Candida auris is a unique fungal pathogen that stands out due to its remarkable evolutionary history, distinctive phenotypic characteristics, and significant clinical implications. The pathogen’s emergence is marked by multiple distinct phylogeographic clades, each having undergone different selective pressures, leading to variations in drug resistance, virulence, and transmissibility.
While C. auris infection presents similarly to candidiasis caused by other Candida species, C. auris is unique in its ability to persist both on the skin and in hospital environments for extended periods. This persistence contributes to its ability to spread within healthcare settings and complicate infection control efforts.
The unique challenges posed by C. auris necessitate a comprehensive approach to management, such as early detection through screening as a critical component to prevent its spread, control outbreaks, and reduce morbidity and mortality.
This new white paper, from Thermo Fisher Scientific, presents a critical approach to preventing healthcare-associated infections through comprehensive screening of C. auris.